Dr. Kasiani Myers, MD
Claim this profileCincinnati Children's Hospital Medical Center
Studies Bone Marrow Failure Syndrome
Studies Pancytopenia Splenomegaly
5 reported clinical trials
9 drugs studied
Area of expertise
1Bone Marrow Failure Syndrome
SAMD9 positive
SAMD9L positive
GATA2 positive
2Pancytopenia Splenomegaly
SAMD9 positive
SAMD9L positive
GATA2 positive
Affiliated Hospitals
Clinical Trials Kasiani Myers, MD is currently running
Treosulfan-Based Conditioning
for Bone Marrow Failure
This trial tests if a combination of three drugs can reduce complications for patients with bone marrow failure diseases. The drugs work by killing harmful cells, stopping their growth, and reducing immune reactions.
Recruiting1 award Phase 211 criteria
Ruxolitinib
for Lung Dysfunction Post Stem Cell Transplant
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy, and lung injury affects as many as 25% of children receiving HSCT. Improved transplant techniques and major improvements in survival mean that HSCT is being more widely used, and more mismatched grafts are being used. Bronchiolitis obliterans (BO) is a major limitation of pediatric HSCT success as BO is commonly diagnosed late in children, when lung injury is irreversible, leading to long term morbidity or even death. Currently, there are major gaps in our knowledge regarding incidence, etiology and optimal treatment of BO following HSCT, and important diagnostic limitations specific to children. Diagnosis of BO is usually based on performance of pulmonary function tests, which is usually impossible in ill children under 10. Even older children who feel unwell or un-cooperative may be unable to produce interpretable data. These deficiencies in diagnosis mean that BO is commonly diagnosed late, meaning fibrosis has occurred and lesions are irreversible. The hypothesis for this interventional trial is that early treatment with standard Flovent/montelukast and steroids plus ruxolitinib will reverse lung injury and reduce the frequency of chronic pulmonary impairment or florid BO.
Recruiting1 award Phase 24 criteria
More about Kasiani Myers, MD
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Kasiani Myers, MD has experience with
- EXG34217
- Fludarabine
- Alemtuzumab
- Cyclosporins
- Mycophenolate Mofetil
- Tacrolimus
Breakdown of trials Kasiani Myers, MD has run
Bone Marrow Failure Syndrome
Pancytopenia Splenomegaly
Bone Marrow Failure
Arterial Tortuosity Syndrome
Telomere Biology Disorders
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kasiani Myers, MD specialize in?
Kasiani Myers, MD focuses on Bone Marrow Failure Syndrome and Pancytopenia Splenomegaly. In particular, much of their work with Bone Marrow Failure Syndrome has involved SAMD9 positive patients, or patients who are SAMD9L positive.
Is Kasiani Myers, MD currently recruiting for clinical trials?
Yes, Kasiani Myers, MD is currently recruiting for 3 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Kasiani Myers, MD has studied deeply?
Yes, Kasiani Myers, MD has studied treatments such as EXG34217, Fludarabine, Alemtuzumab.
What is the best way to schedule an appointment with Kasiani Myers, MD?
Apply for one of the trials that Kasiani Myers, MD is conducting.
What is the office address of Kasiani Myers, MD?
The office of Kasiani Myers, MD is located at: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229 United States. This is the address for their practice at the Cincinnati Children's Hospital Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.